VIVOS THERAPEUTICS INC

VVOSNASDAQ

🏆 #3830 by market capEarnings Aug 18US Equity

$0.31▼ $0.00 (−0.94%)

Live

1h—

24h▼ 0.9%

7d—

14d—

30d—

1y—

🏦Market Cap

$4M

Small Cap

📈Revenue Growth (YoY)

+33.8%

High Growth

📊Gross Margin

61.8%

High

💵FCF Margin

—

⚖️P/S Ratio

0.2x

Cheap

Otter Score

Weak

No chart data available for VVOS.

Trading Snapshot

Day Range: $0.31 – $0.32
52-Week Range: $0.30 – $5.12
Volume: $5.25B
Avg Volume: $3.61B
Shares Outstanding: 13.9M
Next Earnings: Sep 3, 2026

Fundamentals Snapshot

Annual Revenue: $17M
Last Q Revenue: $5M
P/E Ratio: —
P/S Ratio: 0.2x
EPS (TTM): $-2.12
Dividend Yield: —

Why Investors Own VVOS

✓High-growth profile — revenue up +47.4% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 22% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$17M▲ +41.4% YoY

Gross Margin (TTM)

77.9%▲ +1.0% YoY

Operating Income (TTM)

$3M▲ +41.4% YoY

Free Cash Flow (TTM)

$4M▲ +41.4% YoY

About VIVOS THERAPEUTICS INC

Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

🦦